369 related articles for article (PubMed ID: 16122764)
1. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
Nielsen DM
Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
[TBL] [Abstract][Full Text] [Related]
2. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Nielsen DM; Carey GJ; Gold LH
Eur J Pharmacol; 2004 Sep; 499(1-2):135-46. PubMed ID: 15363960
[TBL] [Abstract][Full Text] [Related]
4. Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome.
Taché Y; Martinez V; Million M; Maillot C
Eur J Surg Suppl; 2002; (587):16-22. PubMed ID: 16144197
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression.
Overstreet DH; Keeney A; Hogg S
Eur J Pharmacol; 2004 May; 492(2-3):195-201. PubMed ID: 15178365
[TBL] [Abstract][Full Text] [Related]
6. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
Holsboer F; Ising M
Eur J Pharmacol; 2008 Apr; 583(2-3):350-7. PubMed ID: 18272149
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression.
Overstreet DH; Griebel G
Eur J Pharmacol; 2004 Aug; 497(1):49-53. PubMed ID: 15321734
[TBL] [Abstract][Full Text] [Related]
8. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model.
Iijima M; Chaki S
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):622-7. PubMed ID: 17229509
[TBL] [Abstract][Full Text] [Related]
9. Corticotropin releasing factor receptor antagonists for major depressive disorder.
Paez-Pereda M; Hausch F; Holsboer F
Expert Opin Investig Drugs; 2011 Apr; 20(4):519-35. PubMed ID: 21395482
[TBL] [Abstract][Full Text] [Related]
10. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
Gannon RL; Millan MJ
Brain Res; 2006 Apr; 1083(1):96-102. PubMed ID: 16551464
[TBL] [Abstract][Full Text] [Related]
11. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor.
Gehlert DR; Shekhar A; Morin SM; Hipskind PA; Zink C; Gackenheimer SL; Shaw J; Fitz SD; Sajdyk TJ
Eur J Pharmacol; 2005 Feb; 509(2-3):145-53. PubMed ID: 15733549
[TBL] [Abstract][Full Text] [Related]
12. The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat.
Harro J; Tõnissaar M; Eller M
Neuropeptides; 2001 Apr; 35(2):100-9. PubMed ID: 11384205
[TBL] [Abstract][Full Text] [Related]
13. The neurobiology of depression: inroads to treatment and new drug discovery.
Nemeroff CB; Vale WW
J Clin Psychiatry; 2005; 66 Suppl 7():5-13. PubMed ID: 16124836
[TBL] [Abstract][Full Text] [Related]
14. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats.
Greenwood-Van Meerveld B; Johnson AC; Cochrane S; Schulkin J; Myers DA
Neurogastroenterol Motil; 2005 Jun; 17(3):415-22. PubMed ID: 15916629
[TBL] [Abstract][Full Text] [Related]
15. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
[TBL] [Abstract][Full Text] [Related]
16. New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
Nemeroff CB
Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S13-6. PubMed ID: 12404664
[TBL] [Abstract][Full Text] [Related]
17. The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.
Todorovic C; Jahn O; Tezval H; Hippel C; Spiess J
Neurosci Biobehav Rev; 2005; 29(8):1323-33. PubMed ID: 16099044
[TBL] [Abstract][Full Text] [Related]
18. Ethanol augments GABAergic transmission in the central amygdala via CRF1 receptors.
Nie Z; Schweitzer P; Roberts AJ; Madamba SG; Moore SD; Siggins GR
Science; 2004 Mar; 303(5663):1512-4. PubMed ID: 15001778
[TBL] [Abstract][Full Text] [Related]
19. Disruption of the CRF/CRF1 receptor stress system exacerbates the somatic signs of opiate withdrawal.
Papaleo F; Kitchener P; Contarino A
Neuron; 2007 Feb; 53(4):577-89. PubMed ID: 17296558
[TBL] [Abstract][Full Text] [Related]
20. Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats.
Schwetz I; McRoberts JA; Coutinho SV; Bradesi S; Gale G; Fanselow M; Million M; Ohning G; Taché Y; Plotsky PM; Mayer EA
Am J Physiol Gastrointest Liver Physiol; 2005 Oct; 289(4):G704-12. PubMed ID: 15994424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
